Amol Akhade: Pembrolizumab shows EFS Benefit in Perioperative Head Neck SCC
Amol Akhade shared about Pembrolizumab’s Benefit in Perioperative Head Neck SCC. Read his post on LinkedIn below:
“Pembrolizumab shows EFS Benefit in Perioperative Head Neck SCC.
Keynote 689
Press Release.
It will be interesting to see full data.
Remember Pembrolizumab did not show benefit with CTRT alone in head neck SCC.”
More posts featuring Amol Akhade.
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023